KR20140022786A - 티오세미카르바존 화합물 및 암 치료 용도 - Google Patents

티오세미카르바존 화합물 및 암 치료 용도 Download PDF

Info

Publication number
KR20140022786A
KR20140022786A KR1020137018832A KR20137018832A KR20140022786A KR 20140022786 A KR20140022786 A KR 20140022786A KR 1020137018832 A KR1020137018832 A KR 1020137018832A KR 20137018832 A KR20137018832 A KR 20137018832A KR 20140022786 A KR20140022786 A KR 20140022786A
Authority
KR
South Korea
Prior art keywords
cancer
compound
dp4cych4mt
compounds
dp4e4mt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137018832A
Other languages
English (en)
Korean (ko)
Inventor
데스 알 리처드슨
데이빗 비 러브조이
Original Assignee
데스 알 리처드슨
데이빗 비 러브조이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010905539A external-priority patent/AU2010905539A0/en
Application filed by 데스 알 리처드슨, 데이빗 비 러브조이 filed Critical 데스 알 리처드슨
Publication of KR20140022786A publication Critical patent/KR20140022786A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
KR1020137018832A 2010-12-17 2011-12-16 티오세미카르바존 화합물 및 암 치료 용도 Ceased KR20140022786A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2010905539A AU2010905539A0 (en) 2010-12-17 Dipyridyl Thiosemicarbazone compounds and use in therapy
AU2010905539 2010-12-17
PCT/AU2011/001631 WO2012079128A1 (en) 2010-12-17 2011-12-16 Thiosemicarbazone compounds and use in the treatment of cancer

Publications (1)

Publication Number Publication Date
KR20140022786A true KR20140022786A (ko) 2014-02-25

Family

ID=46243892

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137018832A Ceased KR20140022786A (ko) 2010-12-17 2011-12-16 티오세미카르바존 화합물 및 암 치료 용도

Country Status (10)

Country Link
US (1) US8927580B2 (enExample)
EP (2) EP3287442A1 (enExample)
JP (1) JP5883457B2 (enExample)
KR (1) KR20140022786A (enExample)
CN (1) CN103370308B (enExample)
AU (1) AU2011342378B2 (enExample)
BR (1) BR112013015174A2 (enExample)
CA (1) CA2821984A1 (enExample)
NZ (1) NZ613085A (enExample)
WO (1) WO2012079128A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013015174A2 (pt) 2010-12-17 2020-08-11 Des R Richardson compostos de tio-semicarbazona e aplicação no tratamento de cancer
CA2892011A1 (en) * 2012-11-22 2014-05-30 Oncochel Therapeutics LLC Chemotherapy for drug-resistant cancer cells
CN104177288B (zh) * 2013-05-23 2020-05-01 中国人民解放军军事医学科学院毒物药物研究所 缩氨基硒脲衍生物及其药物组合物和用途
US12383518B2 (en) 2013-11-03 2025-08-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Disulfide-masked pro-chelator compositions and methods of use
US11504346B2 (en) 2013-11-03 2022-11-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Redox-activated pro-chelators
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
WO2017058748A1 (en) * 2015-09-29 2017-04-06 Oncochel Therapeutics, Llc Thiosemicarbazones
CN109052605A (zh) * 2018-07-26 2018-12-21 雷晓琳 一种重金属捕集剂及其制备方法
CN110698511B (zh) * 2019-11-15 2021-09-14 广西师范大学 以2-吡啶甲醛缩氨基硫脲为配体的锡配合物及其合成方法
KR102555030B1 (ko) * 2020-10-19 2023-07-14 고려대학교 산학협력단 티오세미카바존 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4207400A1 (de) * 1992-03-09 1993-09-16 Bayer Ag Hydrazone
EP1608623B1 (en) * 2003-02-05 2011-01-19 Desi Raymond Richardson Metal ion chelators and therapeutic use thereof
AU2003900495A0 (en) * 2003-02-05 2003-02-20 Unisearch Limited Aroylhydrazone derivatives and therapeutic uses thereof
CN1891701A (zh) * 2005-07-07 2007-01-10 桑迪亚医药技术（上海）有限责任公司 杂芳环缩氨基硫脲类化合物及其衍生物和它们在制备抗肿瘤药物中的应用
WO2010000008A1 (en) * 2008-06-30 2010-01-07 Desi Raymond Richardson Thiosemicarbazone compounds and use thereof
BR112013015174A2 (pt) 2010-12-17 2020-08-11 Des R Richardson compostos de tio-semicarbazona e aplicação no tratamento de cancer

Also Published As

Publication number Publication date
CN103370308A (zh) 2013-10-23
EP2651894B1 (en) 2017-08-23
CA2821984A1 (en) 2012-06-21
CN103370308B (zh) 2015-06-17
AU2011342378A1 (en) 2013-08-01
NZ613085A (en) 2015-05-29
EP3287442A1 (en) 2018-02-28
BR112013015174A2 (pt) 2020-08-11
JP5883457B2 (ja) 2016-03-15
US20140206725A1 (en) 2014-07-24
EP2651894A4 (en) 2014-07-09
US8927580B2 (en) 2015-01-06
WO2012079128A1 (en) 2012-06-21
EP2651894A1 (en) 2013-10-23
AU2011342378B2 (en) 2016-09-01
JP2014502599A (ja) 2014-02-03

Similar Documents

Publication Publication Date Title
JP5883457B2 (ja) チオセミカルバゾン化合物および癌の治療における使用
EP3811944B1 (en) Pyrazine derivative as chk1 inhibitor
US20190134056A1 (en) K-ras mutations and antagonists
KR102375288B1 (ko) 대사항암제를 포함하는 항암용 조성물
US9833431B2 (en) Pharmaceutical combinations for the treatment of cancer
HK1216297A1 (zh) 肿瘤溶解综合征的治疗药和预防药
CN116077631A (zh) 涉及粘液素的疾病治疗
US20210221805A1 (en) Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof
US9867807B2 (en) Compositions and methods for drug-sensitization or inhibition of a cancer cell
EP1608623A1 (en) Metal ion chelators and therapeutic use thereof
WO2010000008A1 (en) Thiosemicarbazone compounds and use thereof
TWI753178B (zh) Mcl-1抑制劑與血液癌症標準療法之組合，其用途及醫藥組合物
JP2019510084A (ja) 小分子型の活性酸素種誘導剤及びミトコンドリア活性阻害剤
WO2017058748A1 (en) Thiosemicarbazones
US20210101879A1 (en) AMYLOID PROTEIN-SELECTIVE BACE INHIBITORS (ASBIs) FOR ALZHEIMER?S DISEASE
CN108299390A (zh) 抗肿瘤化合物dcz0415及其制备方法和应用
KR101686411B1 (ko) 피리딘계 유도체를 포함하는 암 예방 또는 치료용 조성물
US20170022215A1 (en) Compounds for Eradicating or Inhibiting Proliferation of Cancer Stem Cells

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130717

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20161209

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170918

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20171128

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180720

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20171128

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20170918

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I